Ex Vivo Patient-Derived Explant Model for Neurofibromatosis Type 1–Related Cutaneous Neurofibromas
Journal of Investigative Dermatology · 2024
DOI: 10.1016/j.jid.2024.01.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2024. Verfasst von Jamie L Grit und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan, USA. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Skin Neoplasms, Neurofibroma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Van Andel Institute, Children's Tumor Foundation.
Abstract (Originalsprache)
Cutaneous neurofibromas (CNFs) are benign tumors that occur in the dermis of individuals with the inherited tumor predisposition disorder, neurofibromatosis type 1. CNFs cause disfigurement, pain, burning, and itching, resulting in substantially reduced QOL in patients with neurofibromatosis type 1. CNFs are benign tumors that exhibit cellular and molecular heterogeneity, making it difficult to develop tractable in vitro or in vivo models. As a result, CNF research and drug discovery efforts have been limited. To address this need, we developed a reproducible patient-derived explant (PDE) ex vivo culture model using CNF tumors from patients with neurofibromatosis type 1. CNF PDEs remain viable in culture for over 9 days and recapitulate the cellular composition and molecular signaling of CNFs. Using CNF PDEs as a model system, we found that proliferation was associated with increased T-cell infiltration. Furthermore, we identified a pattern of reciprocal inflammatory signaling in CNF PDEs in which tumors rely on prostaglandin or leukotriene-mediated signaling pathways. As proof of principle, we show that ex vivo glucocorticoid treatment reduced the expression of proinflammatory genes, confirming that CNF PDEs are a useful model for both mechanistic studies and preclinical drug testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan, USA.
- Pathology and Biorepository Core, Van Andel Research Institute, Grand Rapids, Michigan, USA.
- Optical Imaging Core, Van Andel Research Institute, Grand Rapids, Michigan, USA.
- Corwell Health System, Grand Rapids, Michigan, USA.
- Department of Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan, USA; Corwell Health System, Grand Rapids, Michigan, USA; College of Human Medicine, Michigan State University, Grand Rapids, Michigan, US…
Förderung
- Van Andel Institute
- Children's Tumor Foundation
Zitieren
APA
Grit, J. L., Turner, L., Essenburg, C. J., Gallik, K. L., Dischinger, P. S., Shurlow, N. D., Pate, M. J., Graveel, C. R., & Steensma, M. R. (2024). Ex Vivo Patient-Derived Explant Model for Neurofibromatosis Type 1–Related Cutaneous Neurofibromas. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2024.01.032
Vancouver
Grit JL, Turner L, Essenburg CJ, Gallik KL, Dischinger PS, Shurlow ND, et al. Ex Vivo Patient-Derived Explant Model for Neurofibromatosis Type 1–Related Cutaneous Neurofibromas. Journal of Investigative Dermatology. 2024. doi:10.1016/j.jid.2024.01.032
BibTeX
@article{Grit2024,
author = {Grit, Jamie L and Turner, Lisa and Essenburg, Curt J and Gallik, Kristin L and Dischinger, Patrick S and Shurlow, Nathan D and Pate, Matthew J and Graveel, Carrie R and Steensma, Matthew R},
title = {Ex Vivo Patient-Derived Explant Model for Neurofibromatosis Type 1–Related Cutaneous Neurofibromas},
journal = {Journal of Investigative Dermatology},
year = {2024},
doi = {10.1016/j.jid.2024.01.032}
}
EUVIMED